A Study of LY4175408 in Participants With Advanced Cancer

To join this study, you must have an advanced or spread solid tumour of a specific type: non-small cell lung cancer, small cell lung cancer, womb cancer, or triple-negative breast cancer. For most participants, you should have already tried all standard treatments that your doctor thought were suitable for you, or there aren't any more standard treatments available, or you've chosen not to have them. Some participants in specific groups, however, might be able to join without having had previous treatment for advanced cancer, especially for certain non-small cell lung cancers.

You also need to be generally well enough to take part, as assessed by a quick check of your daily activity level. For some parts of the study, doctors will need to be able to measure your cancer on scans. For specific groups with non-small cell lung cancer, there should be no known genetic changes that other medicines could target, and you might have had limited or no previous treatment for advanced cancer.

You would not be able to join if you have certain other health conditions, such as a history of uncontrolled cancer spread to the brain or spine, serious ongoing infections (like bacterial or viral), or significant heart problems. Also, if you've recently had a certain type of related cancer drug, or have serious side effects that haven't cleared up from previous treatments, this study might not be right for you.

If you decide to take part, the study could last for up to four years. You would receive the study medicine, LY4175408, and potentially other standard cancer treatments. You'll have regular visits to the hospital for checks, which will include blood tests to see how your body is reacting to the medicine and how it's being processed. Scans will also be done to monitor your cancer. The healthcare team will tell you how often these visits will be and what will be involved. Throughout the study, you'll be carefully monitored for any side effects.